Clinical trial
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without…
NCT00309556 · Austrian Breast & Colorectal Cancer Study Group, Other · Completed
Key facts
| NCT number | NCT00309556 |
|---|---|
| Title | Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer |
| Official title | A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ±… |
| Lead sponsor | Austrian Breast & Colorectal Cancer Study Group, Other |
| Collaborators | Amgen Industry Ebewe Pharma GmbH Hoffmann-La Roche Sanofi |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Epirubicin, Docetaxel, Capecitabine, Trastuzumab |
| Enrollment | 536 |
| Start date | Feb 1, 2005 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2011 |
| First posted | Apr 3, 2006 |
| Last update posted | Dec 30, 2011 |
| Countries | Austria |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: